Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer
- PMID: 22194501
- DOI: 10.2214/AJR.10.6342
Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer
Abstract
Objective: The objective of our study was to compare the performance of positron emission mammography (PEM) with that of MRI in the evaluation of the contralateral breast of women with newly diagnosed cancer.
Subjects and methods: Four hundred seventy-two women with newly diagnosed breast cancer offered breast-conserving surgery from September 2006 through November 2008 consented to participate in a multicenter protocol. Participants underwent contrast-enhanced breast MRI and 18F-FDG PEM in randomized order, and the examinations were interpreted independently. The performance characteristics of the imaging modalities were compared using the McNemar test and generalized estimating equations. A retrospective blinded review of PEM images was performed by four experienced observers to understand the reasons for false-negatives.
Results: Three hundred sixty-seven women (median age, 58 years; age range, 26-93 years) eligible for analysis completed the appropriate follow-up for study inclusion. Fifteen women (4.1%) were found to have contralateral cancer (11 invasive [mean tumor size, 12 mm; median, 10 mm; range, 1-22 mm] and four ductal carcinoma in situ). Of the 15 cases, both PEM and MRI showed three (20%), only MRI showed 11 (73%), and one (6.7%) was found at prophylactic mastectomy. MRI sensitivity at 14 of 15 (93%; 95% CI, 66-94) was higher than PEM at three of 15 (20%; 95% CI, 5.3-46) (p<0.001). On PEM, three additional cancers were seen prospectively but were considered probably benign and two other cancers were visible in retrospect at the site. Of 352 contralateral breasts without cancer, findings were negative or benign on PEM for 335 (95.2%; 95% CI, 92.2-97.0), which is more than MRI at 315 (89.5%; 95% CI, 85.7-92.4; p=0.002). The positive predictive value (PPV) of PEM-prompted biopsies (3/14 [21%]) was not significantly different from the PPV of MRI (15/54 [28%], p=0.58). On blinded retrospective PEM review of the 15 contralateral cancers, PEM findings for 11 (73%) were considered suspicious.
Conclusion: Contralateral cancer was found in 15 of 367 women (4.1%), with MRI showing 14 (93%). Eleven contralateral cancers (73%) were visible on PEM, but only three (20%) were recognized prospectively as suspicious. Lesions that are visible on PEM should be viewed as suspicious unless known to be benign by prior breast imaging or biopsy.
Similar articles
-
Breast cancer: comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast.Radiology. 2011 Jan;258(1):59-72. doi: 10.1148/radiol.10100454. Epub 2010 Nov 12. Radiology. 2011. PMID: 21076089 Free PMC article. Clinical Trial.
-
High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer.Breast J. 2006 Jul-Aug;12(4):309-23. doi: 10.1111/j.1075-122X.2006.00269.x. Breast J. 2006. PMID: 16848840 Clinical Trial.
-
Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging.Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):23-36. doi: 10.1007/s00259-010-1588-9. Epub 2010 Sep 25. Eur J Nucl Med Mol Imaging. 2011. PMID: 20871992 Free PMC article. Clinical Trial.
-
Radiologist views of positron emission mammography.Radiol Technol. 2012 Sep-Oct;84(1):18-30. Radiol Technol. 2012. PMID: 22988260 Review.
-
Can supplementary contrast-enhanced MRI of the breast avoid needle biopsies in suspicious microcalcifications seen on mammography? A systematic review and meta-analysis.Breast. 2021 Apr;56:53-60. doi: 10.1016/j.breast.2021.02.002. Epub 2021 Feb 15. Breast. 2021. PMID: 33618160 Free PMC article.
Cited by
-
Clinical utility of positron emission mammography.Proc (Bayl Univ Med Cent). 2013 Jul;26(3):314-9. doi: 10.1080/08998280.2013.11928996. Proc (Bayl Univ Med Cent). 2013. PMID: 23814402 Free PMC article.
-
Nuclear imaging of the breast: translating achievements in instrumentation into clinical use.Med Phys. 2013 May;40(5):050901. doi: 10.1118/1.4802733. Med Phys. 2013. PMID: 23635248 Free PMC article. Review.
-
Comparison of BSGI and MRI as Approaches to Evaluating Residual Tumor Status after Neoadjuvant Chemotherapy in Chinese Women with Breast Cancer.Diagnostics (Basel). 2021 Oct 6;11(10):1846. doi: 10.3390/diagnostics11101846. Diagnostics (Basel). 2021. PMID: 34679544 Free PMC article.
-
Advances in Breast PET Instrumentation.PET Clin. 2024 Jan;19(1):37-47. doi: 10.1016/j.cpet.2023.09.001. PET Clin. 2024. PMID: 37949606 Free PMC article. Review.
-
Reduction of the fluorine-18-labeled fluorodeoxyglucose dose for clinically dedicated breast positron emission tomography.EJNMMI Phys. 2019 Nov 29;6(1):21. doi: 10.1186/s40658-019-0256-9. EJNMMI Phys. 2019. PMID: 31784863 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials